Monte Rosa Therapeutics, Inc. GLUE Future pension and postretirement benefit obligations
Future pension and postretirement benefit obligations at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations?
- Monte Rosa Therapeutics, Inc. (GLUE) reported future pension and postretirement benefit obligations of $5.26M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations increased by 32.8% year-over-year, from $3.96M to $5.26M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s future pension and postretirement benefit obligations has grown at a 37.6% compound annual growth rate (CAGR), from $1.07M to $5.27M.